Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Chief Operating Officer | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 2,154 · Balance 2,154 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Row 2 · 2026-09-16 · Exercise / conversion · Acquired 2,148 · Balance 4,302 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Row 3 · 2026-09-16 · Sale · Disposed 1,659 · Balance 2,643 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.755 to $151.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 4 · 2026-09-16 · Sale · Disposed 989 · Balance 1,654 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.77 to $152.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 5 · 2026-09-16 · Sale · Disposed 1,654 · Balance 0 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.78 to $153.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2029-10-29 | Direct | 2,165 |
Reported balance
After 2026-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-16 · Exercise / conversion · Disposed 2,154 · Balance 2,165 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5: The stock option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2030-10-14 | Direct | 2,148 |
Reported balance
After 2026-09-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-16 · Exercise / conversion · Disposed 2,148 · Balance 2,148 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5: The stock option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.755 to $151.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.77 to $152.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.78 to $153.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5: The stock option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · derivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,148 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,165 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,654 | $153.24 | $253,464.58 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.78 to $153.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 989 | $152.36 | $150,685.72 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,654 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.77 to $152.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,659 | $151.16 | $250,772.62 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,643 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.755 to $151.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-108930 · tm2625628-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · derivative · entry 9 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,296 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · derivative · entry 8 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,319 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 302 | $156.77 | $47,344.54 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 102 | $155.59 | $15,870.16 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.58 to $155.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 400 | $153.00 | $61,199.00 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 404 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.93 to $153.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,998 | $151.80 | $303,292.20 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 804 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.665 to $152.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,500 | $151.39 | $227,085.00 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,802 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.62 to $151.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-099222 · tm2623628-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · derivative · entry 8 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,444 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · derivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,473 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,911 | $150.25 | $287,133.29 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · nonDerivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.79 to $150.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,029 | $149.27 | $153,595.43 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,911 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.79 to $149.765, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 840 | $148.40 | $124,657.51 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,940 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.79 to $148.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 522 | $147.14 | $76,805.25 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,780 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.77 to $147.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-084620 · tm2620681-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · derivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,592 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,627 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 25 | $112.23 | $2,805.75 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,887 | $111.31 | $210,047.25 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.08 to $111.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,390 | $110.26 | $263,519.97 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,912 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.055 to $110.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-076460 · tm2618468-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · derivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,740 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,781 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 48 | $111.90 | $5,370.96 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 891 | $111.30 | $99,165.00 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.89 to $111.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 3,363 | $110.35 | $371,094.94 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 939 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.87 to $110.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-065692 · tm2615383-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · derivative · entry 9 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,888 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · derivative · entry 8 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,935 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F6 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 100 | $130.33 | $13,033.00 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 639 | $129.17 | $82,539.12 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.95 to $129.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 561 | $128.23 | $71,939.78 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 739 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.88 to $128.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,500 | $127.13 | $190,688.10 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.77 to $127.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,502 | $125.96 | $189,198.98 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,800 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.53 to $126.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-044895 · tm2612000-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · derivative · entry 7 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,036 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,089 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 304 | $119.08 | $36,200.84 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · nonDerivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.08 to $119.3767, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.